OECD Home › Science and technology › Innovation in science, technology and industry › Latest Documents
This international conference on "Globalisation and Open Innovation" examined trends in globalisation and "open" models for innovation in firms as well as implications for policy making.
Companies can boost their stock market valuations and lower their cost of capital through improved reporting of intellectual assets and value creation strategies that overcome the limits of accounting standards, according to a report by the OECD.
Further raising its high performance in innovation is of key importance for boosting Switzerland’s economic growth and maintaining high living standards. This review suggests some reforms in innovation policy which would help to cope with this challenge.
This paper examines the extent to which manufacturing output and employment are declining in OECD countries and explores possible causes.
This paper estimates domestic productivity relationships for a sample of 16 OECD countries through probably the most general specification yet.
The Blue Sky II Forum in Ottawa on 25-27 September 2006 will examine new areas for indicator development and set a broad agenda for future work on science, technology and innovation (STI) indicators.
This paper examines the tax treatment of corporate expenditures on selected intellectual assets and develops an indicator of the relative generosity of tax systems in OECD countries to such investments.
English, , 849kb
The 2006 edition OECD Biotechnology Statistics includes data for 23 OECD countries and two observer countries, plus China (Shanghai), and takes a major step forward in improving the comparability of biotechnology indicators among countries.
English, , 436kb
This report documents the growing importance of intellectual assets for firms and the economy more generally and draws a number of implications for policy makers.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.